---
title: "Racura Oncology to List 22,554 New Shares on ASX"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277874800.md"
description: "Racura Oncology Ltd. (AU:RAC) has applied to list 22,554 new fully paid ordinary shares on the ASX, effective March 5, 2026. This issuance results from the exercise of existing options, expanding the company's equity base and enhancing liquidity for shareholders. While the new shares may cause slight dilution, they confirm the conversion of options into traded equity. The latest analyst rating for AU:RAC is a Hold with a price target of A$2.50. Racura Oncology focuses on developing cancer-related therapies and technologies."
datetime: "2026-03-05T03:57:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277874800.md)
  - [en](https://longbridge.com/en/news/277874800.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277874800.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277874800.md) | [繁體中文](https://longbridge.com/zh-HK/news/277874800.md)


# Racura Oncology to List 22,554 New Shares on ASX

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The latest announcement is out from Race Oncology Ltd. ( (AU:RAC) ).

Racura Oncology Ltd has applied for quotation of 22,554 new fully paid ordinary shares on the ASX, to be issued on March 5, 2026. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, modestly expanding the company’s equity base and potentially enhancing liquidity for shareholders.

While the size of the new issuance is relatively small, the move reflects ongoing utilisation of equity-based instruments within Racura Oncology’s capital structure. For investors, the quotation of these shares signals incremental dilution but also confirms that prior options or convertibles are being converted into traded equity, slightly broadening the free float.

The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.

**More about Race Oncology Ltd.**

Racura Oncology Ltd, listed on the ASX under the code RAC, operates in the oncology sector, focusing on the development of cancer-related therapies or technologies. The company targets investors in biotechnology and healthcare markets seeking exposure to oncology-focused innovation.

**Average Trading Volume:** 172,403

**Technical Sentiment Signal:** Buy

**Current Market Cap:** A$407M

### Related Stocks

- [Race Oncology Ltd. (RAC.AU)](https://longbridge.com/en/quote/RAC.AU.md)

## Related News & Research

- [Racura Oncology Seeks ASX Quotation for Additional Ordinary Shares](https://longbridge.com/en/news/279713153.md)
- [Racura Oncology Seeks ASX Quotation for Additional Ordinary Shares](https://longbridge.com/en/news/278818038.md)
- [Racura Oncology Says Recruitment of First Trial Group in Phase One Advanced Solid Tumors Clinical Trial Completed, Shares Jump 12%](https://longbridge.com/en/news/279689677.md)
- [Simble Solutions Files Updated Corporate Governance Statement with ASX](https://longbridge.com/en/news/279501318.md)
- [Neurizon Therapeutics Seeks ASX Quotation for 9.5 Million New Shares](https://longbridge.com/en/news/279692393.md)